id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3138460,e776dab9-33ed-4096-9150-37da7e408176,Q1,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2024,first_quarter,PHA,Monitor Health Data Policy.,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-03-29T12:19:47-04:00
3138511,d6e16179-2c50-47bb-a1ce-17d3411ef53c,Q1,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2024,first_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-01T08:23:59-04:00
3138881,3d77222f-f1e7-4b41-811b-90070fd8c447,Q1,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2024,first_quarter,PHA,"march-in and other Bayh-Dole rights, Prescription Drug Affordability and Access Act, TRACK Act, Medicare drug price negotiation delay periods and exemptions; patent thicket reform, PREVAIL Act, Affordable and Safe Prescription Drug Importation Act, HR5539/S3131 ORPHAN Cures Act; HR5547/S476 Maintaining Investments in New Innovation Act; HR7174, PASTEUR Act, patent thicket reform, biosimilar interchangeability; Medicare drug price negotiation delay periods, expansion to commercial market, march-in and other licensing rights; Pandemic Accord access provisions, Prescription Drug Affordability and Access Act, Pandemic Accord access provisions; public pharmaceutical manufacturing.","Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,88000,0,0,2024-04-02T10:46:25-04:00
3138975,e7423c4b-9da7-41ca-8098-5280709b1e59,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2024,first_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2024-04-02T13:50:47-04:00
3139635,256b7be2-37f2-44b9-a84a-deecf53308c5,Q1,WAKEFERN FOOD CORP.,400588798,WAKEFERN FOOD CORP.,2024,first_quarter,PHA,"Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - ""Lower Costs, More Transparency Act"" S. 3430 - ""Better Mental Health Care, Lower-Cost Drugs, and Extenders Act"" S. 2973 - ""Modernizing and Ensuring PBM Accountability Act"" Legislative measures add more transparency","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-04-04T09:45:30-04:00
3140244,7473185f-c2aa-41ab-83b9-ec794e9945c8,Q1,PENN AVENUE PARTNERS,400918672,"ALKERMES, INC.",2024,first_quarter,PHA,"Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-07T06:39:39-04:00
3140278,e81518cd-18bc-469d-a475-d786e32429b4,Q1,PENN AVENUE PARTNERS,400918672,"UNITEDHEALTH GROUP, INC.",2024,first_quarter,PHA,Pharmacy benefit related issues.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",90000,,0,0,2024-04-07T08:44:48-04:00
3140282,af20bc70-898e-4fb2-8815-3a0fa93dac44,Q1,"4C COMMUNICATIONS, INC.",323717,HEALTHCARE LEADERSHIP COUNCIL,2024,first_quarter,PHA,"H.R. 7050, Substance Use Disorder Workforce Act H.R. 7312, Electronic Prescribing for Controlled Substances 2.0 Act S. 2666, Electronic Prescribing for Controlled Substances Act","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-04-07T10:41:53-04:00
3140325,8715751c-4ff5-418f-bba5-b1eda1676b60,Q1,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2024,first_quarter,PHA,"H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large. H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-04-07T16:52:55-04:00
3140399,500465c7-b868-4d11-845d-02342ef590cb,Q1,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2024,first_quarter,PHA,"Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; PEPFAR; Drug Shortages; Medicaid Generics Penalty.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-08T09:50:20-04:00
3140447,36439ef0-3f60-486e-ba63-f42ad67ffeab,Q1,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2024,first_quarter,PHA,CCAGW Urges House Oversight Committee to Oppose H.R. 6283,HOUSE OF REPRESENTATIVES,,360000,0,0,2024-04-08T10:35:42-04:00
3140700,147ac877-8cbc-47e7-928d-aec040efb936,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ABBOTT LABORATORIES,2024,first_quarter,PHA,"Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-08T16:26:05-04:00
3140764,9901c974-9530-4210-a8ee-c8a75fc674da,Q1,2359 STRATEGIES,401106114,TRAVERE THERAPEUTICS,2024,first_quarter,PHA,Orphan Drug Act,"HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2024-04-08T20:03:07-04:00
3141001,5b18d3e0-5096-4166-82b7-9eb5a78e7321,Q1,EMERGENT STRATEGIES,401104778,"GENBIOPRO, INC.",2024,first_quarter,PHA,FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS).,"HOUSE OF REPRESENTATIVES,SENATE",35000,,0,0,2024-04-09T11:44:30-04:00
3141108,f89973b0-d06d-43cb-84cd-ab112b6802a5,Q1,"MASON STREET CONSULTING, LLC",401105150,CAPITAL RX INC.,2024,first_quarter,PHA,PBM Reform.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-09T14:26:32-04:00
3141127,da292256-322c-43f3-8e90-c1f0b26d012c,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2024,first_quarter,PHA,"Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-09T15:42:49-04:00
3141140,e7e593da-3331-4b25-b5af-14b5a1cb1e5d,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2024,first_quarter,PHA,General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. Issues related to Drug Enforcement Administration Pseudoephedrine quotas.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-09T16:01:29-04:00
3141147,c21cbecf-abf6-479a-bf9e-e7bfd7f7b871,Q1,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CVS HEALTH,2024,first_quarter,PHA,"Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R. 1770 and S. 2477, the Equitable Community Access to Pharmacist Services Act. Issues related to prescription drug access and affordability.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-09T16:10:39-04:00
3141240,15b7ee53-2dfb-418e-b789-4168ada80f23,Q1,TRUSYNERGY,401107715,BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.),2024,first_quarter,PHA,Oversight of the Strategic National Stockpile to promote safer and more effective treatments in the stockpile; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; FY 24 LHHS appropriations; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; increasing domestic manufacturing and onshoring of treatments and their components; BARDA funding and oversight; IBMSC funding and oversight; FY 25 LHHS appropriations; MCM PRV,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-04-10T06:25:33-04:00
3141684,1aa2128d-aa21-472e-b1c9-90a0bbf94ade,Q1,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2024,first_quarter,PHA,"Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-10T20:30:44-04:00
3142371,b9579401-f3ff-469c-8c14-ef9270157af6,Q1,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2024,first_quarter,PHA,"Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-12T10:22:07-04:00
3142760,f356a8c3-e2e5-4f7e-b5eb-93ddc31fa066,Q1,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2024,first_quarter,PHA,"IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act CMS Implementation of PY 2024 Medicare Part D drug rule CMS Implementation of drug provisions of the IRA 2022.","Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE",,130000,0,0,2024-04-12T14:20:59-04:00
3142850,1cfb5183-d465-476b-888a-6ffaac3035dd,Q1,PANNONE LOPES DEVEREAUX & O'GARA LLC,401105501,AMGEN,2024,first_quarter,PHA,Prescription drug pricing.,,9000,,0,0,2024-04-12T15:42:59-04:00
3142889,ff3ff60e-3462-43b2-b6ab-46df946bdc65,Q1,DENTONS US LLP,36105,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA,2024,first_quarter,PHA,Federal issues impacting workforce and innovation in the pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-12T16:02:06-04:00
3143269,e353961c-d642-43c7-b862-dae7cda04fca,Q1,FORBES-TATE,400976792,CALIFORNIA LIFE SCIENCES ASSOCIATION,2024,first_quarter,PHA,Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-04-12T19:30:12-04:00
3143420,8fd3d1cb-eeb9-455d-a076-2d984386d4bb,1T,KING & SPALDING LLP,21632,"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)",2024,first_quarter,PHA,Advocacy on low income subsidy benefits,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2024-04-12T21:25:44-04:00
3143450,1b9ee0db-1be8-4495-a398-984eb3f8c550,Q1,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2024,first_quarter,PHA,"340B, Hospital at Home","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,35600,0,0,2024-04-13T09:16:53-04:00
3143746,7fbcf3d8-414f-452e-858a-3c854617d216,Q1,FORBES-TATE,400976792,PHRMA,2024,first_quarter,PHA,Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-04-13T22:50:39-04:00
3143833,3bb84907-976c-43f8-a7f8-76dc59156607,Q1,FORBES-TATE,400976792,INDEPENDENT PHARMACY COOPERATIVE,2024,first_quarter,PHA,"Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023, Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act, Issues related to H.R. 3561 - PATIENT Act of 2023, Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act. Issues related to H.R. 5378 - the Lower Costs, More Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-14T11:29:33-04:00
3144490,115a181f-3c88-4a90-9fe7-e928f171f636,Q1,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2024,first_quarter,PHA,"H.R. 1839/S. 993 Combatting Illicit Xylazine Act H.R. 4531 SUPPORT Act S. 3393 SUPPORT for patients and Communities Reauthorization Act, review of language related to xylazine for potential inclusion","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",,380000,0,0,2024-04-15T09:55:55-04:00
3145044,915d4b15-2fad-486e-af7e-e4a47b83816e,Q1,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,3446,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,2024,first_quarter,PHA,HR 1770 - Provider status legislation for pharmacists Access to long-term care pharmacy services for home-based patients Access to vaccines for long-term care residents Cybersecurity attack on Change Healthcare,"Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,15000,0,0,2024-04-15T13:55:30-04:00
3145146,4dd0ce12-2af7-43ec-a5be-3e1ba6939b4f,Q1,THE CONSILIO GROUP,400374717,PARATEK PHARMACEUTICALS,2024,first_quarter,PHA,"Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use","Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office",36000,,0,0,2024-04-15T14:35:16-04:00
3145327,1756a548-dd6f-467e-bb17-f65475003b29,Q1,FOLEY & LARDNER LLP,15042,"ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY",2024,first_quarter,PHA,Issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience.,"HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-04-15T15:47:13-04:00
3145686,406e049f-c018-4468-86ea-c2d8185c0e13,Q1,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,WALGREEN CO.,2024,first_quarter,PHA,Pharmacist provider status Issues related to drug pricing Issues related to access and distribution of pharmaceutical products,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",50000,,0,0,2024-04-15T17:54:39-04:00
3146235,2d974d90-8318-4175-9d1d-7bc588fe97f3,Q1,WAXMAN STRATEGIES,401103693,340B HEALTH,2024,first_quarter,PHA,Issues affecting the 340B drug pricing program; Appropriations for 340B program.,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2024-04-16T11:50:32-04:00
3146272,20019fbf-4bdf-415b-a2cb-3a837e92f579,Q1,THE MATHIS HARPLE GROUP,322911,PHRMA,2024,first_quarter,PHA,"Price Controls, Intellectual Property Rights S.127 S.113 S.1339","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-04-16T11:54:41-04:00
3146448,2a852fa2-51e0-4a8f-b68e-2f6a764ca885,Q1,THE MATHIS HARPLE GROUP,322911,PILMA,2024,first_quarter,PHA,"Price Controls, Intellectual Property Rights S.127, S.113, S.1339","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-04-16T13:01:55-04:00
3146702,73fcd0e8-2377-4cb0-b098-220b2edc0ccd,Q1,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2024,first_quarter,PHA,Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA),"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2024-04-16T14:29:08-04:00
3147110,b56ca7fd-a7cb-4f5f-9ef9-e1bb3d55560c,Q1,60 PLUS ASSOCIATION,41988,60 PLUS ASSOCIATION,2024,first_quarter,PHA,"Urging Members of Congress and the Biden Administration to support and advance the Equitable Community Access to Pharmacist Services Act (H.R. 1770, S. 2477) to provide payment for essential pharmacist services under Medicare Part B and ensure pharmacists can continue to protect seniors from the threat of COVID-19, influenza, RSV, strep throat, pneumococcal, and hepatitis B.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",,,0,0,2024-04-16T15:48:29-04:00
3147196,4498e81b-e77e-4098-a2f9-db4f64bb5e8b,Q1,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2024,first_quarter,PHA,OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas,"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",168788,,0,0,2024-04-16T16:06:57-04:00
3147652,c4513bc0-c173-49a5-ab85-9d1002b1f8b2,Q1,AARP,1694,AARP,2024,first_quarter,PHA,"No bill number. Discussed the Medicare Prescription Payment Plan program. H.R. 5385, the Medicare PBM Accountability Act. H.R. 5372, Expanding Seniors Access to Lower Cost Medicines Act of 2023. H.R. 2880, Protecting Patients Against PBM Abuses Act. H.R. 5539, the Optimizing Research Progress Hope and New (ORPHAN) Cures Act. H.R. 5547, the Maintaining Investments in New Innovation (MINI) Act. S. 79, the Interagency Patent Coordination and Improvement Act of 2023. S. 150, the Affordable Prescriptions for Patients Act of 2023. S. 113, the Prescription Pricing for the People Act of 2023. S. 142, the Preserve Access to Affordable Generics and Biosimilars Act. S. 148, the Stop STALLING Act. No bill number. Discussed the Reducing Drug Prices for Seniors Act. No bill number. Discussed the Inflation Reduction Act.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,4370000,0,0,2024-04-17T08:46:01-04:00
3147795,5f4c5e39-6f5a-4c62-aa16-5b0ff5b682a3,Q1,"DESIMONE CONSULTING, LLC",400931695,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2024,first_quarter,PHA,"Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-17T09:56:07-04:00
3148721,f40e73db-3678-4df8-a6e0-e57ac83a50ec,Q1,HARMONY BIOSCIENCES,401105020,HARMONY BIOSCIENCES,2024,first_quarter,PHA,Issues related to the development and approval of rare disease treatments,"HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2024-04-17T13:19:52-04:00
3148950,8df2c3e4-f569-4797-9ab7-de79c838732d,Q1,PRIME POLICY GROUP,400532589,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2024,first_quarter,PHA,H.R.1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; S.2666 - EPCS 2.0 Act,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2024-04-17T14:04:29-04:00
3149011,d68658e4-c51d-4820-8818-13c7864ad188,Q1,MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP),24566,MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS,2024,first_quarter,PHA,"H.R. 1835: Saving Access to Laboratory Services Act; H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,1580000,0,0,2024-04-17T14:22:13-04:00
3149296,3083ee6c-ff9d-437b-bbf6-f9f304d35c64,Q1,"NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)",28264,NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD),2024,first_quarter,PHA,Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. Rare Pediatric Disease Priority Review Vouchers (RDP-PRV). Pediatric Study Requirements. Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-04-17T15:26:00-04:00
3149555,b2842b8e-006d-43d5-a62a-4c1bed844934,Q1,DA VINCI GROUP,11548,"BOESEN & SNOW, LLC",2024,first_quarter,PHA,"Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-04-17T16:35:27-04:00
3149676,eefc694f-26a8-4aab-8890-499ba400d634,Q1,PRIME POLICY GROUP,400532589,"QUVA PHARMA, INC.",2024,first_quarter,PHA,"Legislation and regulation impacting outsourcing facilities regulated under Section 503B under the Federal Food, Drug, and Cosmetic Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-17T17:09:35-04:00
3149840,df9d2982-03b5-4910-b374-b1616d8f5acc,Q1,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2024,first_quarter,PHA,"Health-related issues including reimbursement, research, public-health & clinical care.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2024-04-17T18:03:43-04:00
3149867,46b22b57-2edd-4328-ac69-870893542e76,Q1,ARENTFOX SCHIFF LLP,4208,"AMERICAN PHARMACY COOPERATIVE, INC.",2024,first_quarter,PHA,"Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-17T18:13:07-04:00
3149880,dab653d7-c17c-437c-9c88-562ca416d481,Q1,BLUE SHIELD OF CALIFORNIA,6518,BLUE SHIELD OF CALIFORNIA,2024,first_quarter,PHA,"H.R.5378 - Lower Costs, More Transparency Act; provisions related to pharmacy benefit managers.","HOUSE OF REPRESENTATIVES,SENATE",,110000,0,0,2024-04-17T18:17:57-04:00
3149915,a9671007-67f6-4f23-8545-145b17519189,Q1,"PORT SIDE STRATEGIES, LLC",401105394,SOCIAL SECURITY WORKS,2024,first_quarter,PHA,Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-04-17T18:42:40-04:00
3149921,66035456-9c6f-4f6a-9456-13831f8e6be8,Q1,"PORT SIDE STRATEGIES, LLC",401105394,NEW VENTURE FUND,2024,first_quarter,PHA,Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.4895 - Lowering Drug Costs for American Families Act - in support. H.R.485 - Protecting Health Care for All Patients Act of 2023 - opposed.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-04-17T18:44:11-04:00
3149935,1576d727-dc13-41d3-a0cb-1c8ab3bba27a,Q1,"PORT SIDE STRATEGIES, LLC",401105394,CENTER FOR HEALTH AND DEMOCRACY,2024,first_quarter,PHA,"Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. H.R.5378 - Lower Costs, More Transparency Act - in support. S.2973 - Modernizing and Ensuring PBM Accountability Act - in support. Issues related to expanding out-of-pockets costs.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",20000,,0,0,2024-04-17T18:45:49-04:00
3150471,5be60241-4551-4b9c-89ad-fb9c6790e81d,Q1,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"LILLY USA, LLC",2024,first_quarter,PHA,Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act,"HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-04-18T10:31:55-04:00
3150622,fc95e1de-79e3-467d-aa9e-fc7c2beef1b0,Q1,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2024,first_quarter,PHA,"COVID Therapeutics; Cell and Gene Therapy; Step Therapy HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,210000,0,0,2024-04-18T11:01:27-04:00
3150662,b39805a9-1ccd-4226-a379-bb23c061e710,Q1,GUIDEWELL MUTUAL HOLDING CORPORATION,401103191,GUIDEWELL MUTUAL HOLDING CORPORATION,2024,first_quarter,PHA,"COVID Therapeutics; Cell and Gene Therapy; Step Therapy HR 5372 (118th Congress), Expanding Seniors' Access to Lower Cost Medicines Act of 2023, by Rep. John Joyce (R-PA). To amend Title XVIII of the Social Security Act to facilitate midyear formulary changes for biosimilars. HR 5376 (117th Congress), Inflation Reduction Act of 2022, by Rep. John Yarmuth (D-KY). Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. HR 7312 (118th Congress), EPCS 2.0 Act, by Rep. Ann Kuster (D-NH). To provide requirements for electronic prescribing for controlled substances under group health plans and group and individual health insurance coverage.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,10000,0,0,2024-04-18T11:05:55-04:00
3150702,4ad2699d-ed97-4a64-b1a6-efb1bff1a914,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,AIM IMMUNOTECH INC.,2024,first_quarter,PHA,Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-04-18T11:11:25-04:00
3150740,c2302ec3-5f68-4b81-9d72-3eafe7abe468,Q1,AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION,1331,AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION,2024,first_quarter,PHA,"Lobby members of Congress to implement oversight of the FDA regarding the importance of sunscreen use during the proposed rule to put into effect a final monograph for nonprescription, over-the-counter (OTC) sunscreen drug products. Advocate for a stable supply of medications and mitigate drug shortages. Advocate for increased transparency regarding drug pricing. Advocate for reducing barriers to entry of generic drugs into the marketplace. Advocate for transparency on the part of pharmaceutical benefit managers. Advocate for patient access to compounded medications. Advocate for reducing the burdens of utilization management tools, including step therapy and prior authorization for pharmaceuticals. Advocate for implementation of language to direct the Secretary of Health and Human Services to open a public docket for the submission of public comments regarding factors that should be taken into consideration when reviewing a proposed modification to an approved risk evaluation and mitigation strategy, and for other purposes (enacted as part of P.L. 117-328, Consolidated Appropriations Act, 2023, H.R. 2617). Support S. 127, Pharmacy Benefit Manager Transparency Act Support H.R. 830/ S. 1375, the Help Ensure Lower Patient (HELP) Copays Act. Support S. 935, the Fair Accountability & Innovative Research (FAIR) Drug Pricing Act Support H.R. 2630/S. 652, Safe Step Act. Support H.R. 167, Patient Access to Urgent-Use Pharmacy Compounding Act","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,700000,0,0,2024-04-18T11:24:09-04:00
3150788,72522a53-10c5-49d5-9263-000060cd32f4,Q1,BUCHANAN INGERSOLL & ROONEY PC,55291,GENERIC ANIMAL DRUG ALLIANCE,2024,first_quarter,PHA,"Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-18T11:37:51-04:00
3150824,84ace21e-e71b-4f9e-82b8-63828f6dc4f3,Q1,NATIONAL RURAL LETTER CARRIERS' ASSOCIATION,28526,NATIONAL RURAL LETTER CARRIERS' ASSOCIATION,2024,first_quarter,PHA,"H.R. 6283,""DRUG Act""- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, ""DRUG Act""- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill.","HOUSE OF REPRESENTATIVES,SENATE",,125000,0,0,2024-04-18T11:44:27-04:00
3150956,391d599e-9288-41ec-9123-491a93f51c79,Q1,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"CENCORA, INC.",2024,first_quarter,PHA,Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-18T12:08:03-04:00
3150969,6e1300ad-2a82-474f-b9cd-4065f8ef7558,Q1,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2024,first_quarter,PHA,"Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. The PROTECT 340B Act (H.R. 2534) and the 340B Pharmaceutical Access to Invest in Essential, Needed Treatments & Support Act of 2024 (H.R. 7635), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to pharmacy residency funding (generally, no specific legislation). Issues related to drug price negotiations and patient out-of-pocket costs (generally, no specific legislation). Issues related to authorization of technician product verification (generally, no specific legislation). The Biosimilar Red Tape Elimination Act (S. 2305), issues related to accelerating biosimilar adoption.","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,240000,0,0,2024-04-18T12:11:57-04:00
3151005,090d5a50-d0b9-4337-9056-ba14ccec9471,Q1,SEWARD SQUARE GROUP,400478356,RITE AID CORPORATION,2024,first_quarter,PHA,Advised on the Equitable Community Access to Pharmacist Services Act is a PBM reform bill.,"Health & Human Services, Dept of (HHS)",50000,,0,0,2024-04-18T12:24:27-04:00
3151145,a5a0e9c6-2814-4c48-b9ea-c98d25f6b656,Q1,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2024,first_quarter,PHA,Prescription Drug Pricing Reform; Pharmacy Benefit Managers; Delinking PBM language S. 1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage,"HOUSE OF REPRESENTATIVES,SENATE",,200000,0,0,2024-04-18T12:53:03-04:00
3151264,d91155cc-b766-47ce-856c-21572f853601,Q1,OREGON HEALTH & SCIENCE UNIVERSITY,30291,OREGON HEALTH & SCIENCE UNIVERSITY,2024,first_quarter,PHA,"Support for 340B Drug Discount Program and resulting patient and community benefits provided through participating safety-net hospitals and other covered entities; opposition to imposing administrative burden to the program through new mandatory reporting requirements beyond regular HRSA audits, and policy limiting the scope and drug discounts provided under of the program; and support for Congressional and/or Administration action to prohibit pharmaceutical manufacturer denials of 340B drug discounts to safety-net hospitals and other 340B covered entities.","HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-04-18T13:10:23-04:00
3151616,1ddacf6a-e814-4915-9edb-62bc19c2e2a9,Q1,BURRELL INTERNATIONAL GROUP LLC,401103483,TONIX PHARMACEUTICALS HOLDING CORP.,2024,first_quarter,PHA,"LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-04-18T13:49:26-04:00
3151628,ddb5bf88-be2c-467c-ad9e-0c5d036ee3d9,Q1,BURRELL INTERNATIONAL GROUP LLC,401103483,SHIONOGI INC.,2024,first_quarter,PHA,"Pandemic and All Hazards Preparedness Act, FY24 LHHS Funding for MCM Development; H.R.2940/S.1355.PASTEUR Act of 2023","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-18T13:50:18-04:00
3151649,095d57d4-9b9d-4c0f-88f4-c9111a65c5a8,Q1,MASSACHUSETTS MEDICAL SOCIETY,23975,MASSACHUSETTS MEDICAL SOCIETY,2024,first_quarter,PHA,"Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill S. 470/HR 977, The Patient Access to Higher Quality Health Care Act","HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-04-18T13:51:38-04:00
3151790,197d75a7-652d-4829-b7c4-e70e656ed971,Q1,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2024,first_quarter,PHA,Hospital discounts; 340B program,"HOUSE OF REPRESENTATIVES,SENATE",,1730000,0,0,2024-04-18T14:10:16-04:00
3151811,e07c90c1-78bb-466a-baf8-ff14938b0a52,Q1,SHIONOGI INC.,401107081,SHIONOGI INC.,2024,first_quarter,PHA,"Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,120000,0,0,2024-04-18T14:15:25-04:00
3151834,cb2c6ec7-2e7b-41f1-9586-c78e766664d9,1A,BURRELL INTERNATIONAL GROUP LLC,401103483,SHIONOGI INC.,2024,first_quarter,PHA,"FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Priority Review Voucher and MCM Development funding","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-18T14:20:39-04:00
3151850,0f41f0e8-b64e-412d-a673-f960ef3662b7,1A,BURRELL INTERNATIONAL GROUP LLC,401103483,TONIX PHARMACEUTICALS HOLDING CORP.,2024,first_quarter,PHA,"LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-04-18T14:22:46-04:00
3152060,1a505080-2c8c-4068-ba9b-98f85ce6d1c3,Q1,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2024,first_quarter,PHA,Issues relating to the prevention and mitigation of pharmaceutical shortages.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-18T14:49:10-04:00
3152142,79424a12-af50-470d-8b62-fa880536070a,Q1,E3 STRATEGIC CONSULTING GROUP,401104104,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2024,first_quarter,PHA,"Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act""); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-18T14:55:23-04:00
3152161,1b55dae8-b511-4b9c-912b-8ebf79bcea38,Q1,BRAVO GROUP,296293,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2024,first_quarter,PHA,"Biopharmaceutical issues including: social and economic, value of the biopharmaceutical sector, patient access and safety issues, drug importation, life science innovation, and job impact.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-04-18T14:56:57-04:00
3152224,ce519119-c1f9-463a-bd0b-d10edfca554c,Q1,HANCE SCARBOROUGH,17443,ALLIANCE FOR PHARMACY COMPOUNDING,2024,first_quarter,PHA,"Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-18T15:07:43-04:00
3152370,21294716-540c-482f-98ff-53050b2ad67c,Q1,FROST BROWN TODD LLC,283572,DISPOSERX,2024,first_quarter,PHA,Support Act,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-04-18T15:29:17-04:00
3152418,3d23fdd9-b153-4038-ba9a-3cc5e870ba53,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2024,first_quarter,PHA,N/A,"HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2024-04-18T15:35:24-04:00
3152453,b3e91923-9073-45a2-92b1-120cc9082cec,1A,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2024,first_quarter,PHA,Monitoring biotech legislation; prescription drug prices; Infrastructure Legislation,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-04-18T15:40:34-04:00
3152466,d22a485a-3b69-477b-b25a-17a86f91ccbb,Q1,HB STRATEGIES,401104718,BAYER U.S. LLC,2024,first_quarter,PHA,"Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically.","HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2024-04-18T15:46:16-04:00
3152608,9a16d9f7-602b-4720-8c04-7af0ed176d73,Q1,HANCE SCARBOROUGH,17443,BOEHRINGER INGELHEIM USA CORPORATION,2024,first_quarter,PHA,"Provide ongoing animal health policy monitoring, assessment, and research support. Farm Bill.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-04-18T16:18:36-04:00
3152768,df659c99-dec7-4646-a0dc-2100ac4e3869,Q1,THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,401104060,THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,2024,first_quarter,PHA,"Lobbying to improve prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining utilization management processes. The Medicare Part D Six Protected Classes Policy: requires Part D plan to cover all drugs in six classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals, and antineoplastics. For people living with Parkinson's, most of whom are Medicare beneficiaries, it is essential to have access to wide range of treatment options for antidepressants and antipsychotics. Parkinson's causes non-motor symptoms, including depression and psychosis, and individuals often experience different side effects, reactions, and efficacy based on which medications they take. Lobbying the Centers for Medicare and Medicaid Services to direct Durable Medical Equipment Medicare Administrative Contractors to provide additional clarification regarding the use of claim modifiers for DME therapies that require administration via an external infusion pump to expedite patient access once new Parkinson's therapies receive approvals from the Food and Drug Administration. H.R.2360/S.652/S.1339 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Led an digital campaign to allow constituents to write their members of Congress in support of this legislation.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2024-04-18T17:02:21-04:00
3152817,55749dda-cc46-4dad-90a3-b60e0126a53f,Q1,COREWELL HEALTH,298455,COREWELL HEALTH,2024,first_quarter,PHA,340B PBM Reform/Oversight Regulation of controlled substances via telehealth prescribing practices Transparency and high costs associated with prescription drugs,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE",,180000,0,0,2024-04-18T17:17:19-04:00
3153370,8c2e1310-723f-4fdf-82b1-4db9f0e34cc9,Q1,"MARSHALL & POPP, LLC",401105121,ABBVIE INC.,2024,first_quarter,PHA,"Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-18T23:57:56-04:00
3153376,6330d448-c4b9-4614-8c04-e0b4b25f293e,Q1,"MARSHALL & POPP, LLC",401105121,AMGEN USA INC.,2024,first_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.Res. 496 and S.Res.566 - National Cholesterol Education Month. S. 3558, Biosecure.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-19T00:06:31-04:00
3153389,0b3f603b-f368-4f77-861a-e90fa3229117,Q1,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2024,first_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-19T00:24:46-04:00
3153403,7a7e74ae-c7e0-45b6-a19d-56b63d82a3a6,Q1,"MARSHALL & POPP, LLC",401105121,"PFIZER, INC.",2024,first_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-19T00:29:00-04:00
3153406,fa1e54b8-ff8d-40b4-b7d7-cce39bae3a33,Q1,"MARSHALL & POPP, LLC",401105121,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2024,first_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R.2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R.4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. S.3558, Biosecure.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-04-19T00:31:09-04:00
3153410,4a94a7e2-e06a-4db3-aaf0-f558883849f1,Q1,"MARSHALL & POPP, LLC",401105121,"SANOFI U.S. SERVICES, INC.",2024,first_quarter,PHA,"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R.5378 - Lower Costs, More Transparency Act, and H.R. 4366, Consolidated Appropriations Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-04-19T00:32:55-04:00
3153872,f5fac367-c07e-4f40-8281-5cb5cea7fa59,Q1,"MEHLMAN CONSULTING, INC.",284950,"AARP, INC.",2024,first_quarter,PHA,Issues related to the cost of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-19T09:29:19-04:00
3153927,b5256b7f-df35-4462-8ac0-cbed5010e865,Q1,NATIONAL GROCERS ASSOCIATION,27924,NATIONAL GROCERS ASSOCIATION,2024,first_quarter,PHA,Protect Patient Access to Pharmacies Act Pharmacy Direct and Indirect Remuneration Fee Reform Pharmacy Benefit Manager Transparency Pharmacy Quality Measures Standardized pharmacy performance measures Any Willing Pharmacy,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,178466,0,0,2024-04-19T09:36:48-04:00
3154131,96e16f02-dcd0-494f-92f7-df5b0c77e032,Q1,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2024,first_quarter,PHA,Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA),"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,540662,0,0,2024-04-19T09:56:01-04:00
3154434,68fda28d-d081-4aa0-9da3-f4bd896a9ba6,Q1,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2024,first_quarter,PHA,Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-19T10:20:42-04:00
3154436,55abbb07-89dc-4b93-ae07-e7459fc3f865,Q1,FAEGRE DRINKER BIDDLE & REATH LLP,12631,"VERDE ENVIRONMENTAL TECHNOLOGIES, INC.",2024,first_quarter,PHA,Drug safety.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",20000,,0,0,2024-04-19T10:20:53-04:00
3154591,e9d00358-48c2-4d38-9f17-98022dd49acb,Q1,FAEGRE DRINKER BIDDLE & REATH LLP,12631,ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL),2024,first_quarter,PHA,"Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-04-19T10:32:06-04:00
3154605,947b6a69-1f4f-4f93-84d6-0d7fd41705a0,Q1,AKIN GUMP STRAUSS HAUER & FELD,682,CENTRIENT PHARMACEUTICALS LLC,2024,first_quarter,PHA,Issues related to onshoring supply chains and biomanufacturing of essential medicines to the United States.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-04-19T10:33:24-04:00
3154701,c14fc470-ecb6-4e67-8460-1d29ea521d9d,Q1,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2024,first_quarter,PHA,Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-19T10:41:14-04:00
3154775,173df5e5-5a5a-4b63-9cf0-a774119bb567,Q1,"MEHLMAN CONSULTING, INC.",284950,ASSOCIATION OF ACCESSIBLE MEDICINES,2024,first_quarter,PHA,Drug shortages. S. 775 - Increasing Transparency in Generic Drug Applications Act.,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-04-19T10:47:32-04:00
3154826,11b170bd-e554-4691-86a6-ee42575f6879,Q1,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2024,first_quarter,PHA,"340B Drug Pricing Program, Patient Co-pays Legislation (H.R. 830), Medicare Coverage",HOUSE OF REPRESENTATIVES,20000,,0,0,2024-04-19T10:52:30-04:00